Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans

Dapagliflozin, a selective sodium–glucose co-transporter-2 inhibitor, and linagliptin, a competitive, reversible dipeptidyl peptidase-4 inhibitor, are commonly prescribed antidiabetic medications in general clinics. Since there are several merits to combining them in a fixed-dose combination product...

Cijeli opis

Bibliografski detalji

Glavni autori:	Jin-Woo Park, Jong-Min Kim, Ji Hyeon Noh, Kyoung-Ah Kim, Hyewon Chung, EunJi Kim, Minja Kang, Ji-Young Park
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2022-03-01
Serija:	Pharmaceutics
Teme:	dapagliflozin linagliptin fixed-dose combination products bioequivalence
Online pristup:	https://www.mdpi.com/1999-4923/14/3/591
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!